[{"id":"d0b6a163-4818-41af-9aae-cc62ea1a993c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03838367","created_at":"2021-01-18T18:56:51.338Z","updated_at":"2024-07-02T16:36:15.074Z","phase":"Phase 1/2","brief_title":"Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC","source_id_and_acronym":"NCT03838367","lead_sponsor":"CytoDyn, Inc.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vyrologix (leronlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/22/2019","start_date":" 04/22/2019","primary_txt":" Primary completion: 07/15/2022","primary_completion_date":" 07/15/2022","study_txt":" Completion: 09/16/2022","study_completion_date":" 09/16/2022","last_update_posted":"2022-03-21"},{"id":"6fd84c97-f385-402f-96cc-d8585cf1e544","acronym":"","url":"https://clinicaltrials.gov/study/NCT04313075","created_at":"2021-01-18T20:54:24.625Z","updated_at":"2024-07-02T16:36:17.832Z","phase":"","brief_title":"A Compassionate Use Study of Leronlimab in Breast Cancer","source_id_and_acronym":"NCT04313075","lead_sponsor":"CytoDyn, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyrologix (leronlimab)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-01-28"}]